<DOC>
	<DOCNO>NCT03043053</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled study effect intranasal oxytocin obese adult , age 18-45 year old . Subjects randomized receive intranasal oxytocin placebo ( 3 spray per nostril , 4 time per day ) 8 week . Study visit include screen determine eligibility , 2-part baseline visit , visit every 2 week thereafter week 14 , safety follow-up visit 6 week last dose study drug . Study procedure include behavioral , metabolic , neuroimaging , endocrine assessment .</brief_summary>
	<brief_title>The Effects Oxytocin Obese Adults</brief_title>
	<detailed_description />
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1845 year old ; BMI 3045 kg/m2 Use drug affect metabolism , glucose , appetite ; history medication change within 4 week enrollment ; active substance use ; history cardiovascular disease , gastrointestinal disorder , bariatric surgery , epilepsy , untreated thyroid disease ; hematocrit &gt; 2 % normal ; fast glucose &gt; 125 mg/dL ; ALT AST &gt; 2.5 time upper limit normal ; Cr &gt; 1.5 mg/dL ; hyponatremia ; pregnancy breastfeeding ; unwilling use medically acceptable form contraception ( female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>weight loss</keyword>
	<keyword>body mass index</keyword>
	<keyword>oxytocin</keyword>
	<keyword>magnetic resonance imaging</keyword>
</DOC>